Trevi Therapeutics, Inc. (TRVI) delivered a return of 183.53% over the past year. Since TRVI does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Trevi Therapeutics, Inc. one year ago would be worth $28,353 today, representing a gain of $18,353.

Trevi Therapeutics, Inc. (TRVI) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For TRVI, the total return equals the price-only return.

Yes, Trevi Therapeutics, Inc. (TRVI) outperformed the S&P 500 by 158.54 percentage points over the past year. TRVI delivered a total return of 183.53%, compared to the S&P 500's 24.99%. This 158.54pp alpha means investors in TRVI earned more than a passive S&P 500 index fund.

Trevi Therapeutics, Inc. (TRVI) experienced a maximum drawdown of -29.50% over the past year, declining from its peak on 2025-12-10 to its trough on 2026-01-23. The stock recovered to its prior peak by 2026-04-15. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Trevi Therapeutics, Inc. (TRVI)'s long-term returns with dividends reinvested. Over 10 years, the total return is 118.1% (8.1% CAGR) — $10,000 would have grown to $21,812. Over 20 years: 118.1% total return (4.0% CAGR) — $10,000 → $21,812. Over 30 years: 118.1% total return (2.6% CAGR) — $10,000 → $21,812. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Trevi Therapeutics, Inc.'s best calendar year was 2024 with a total return of 216.9%. Its worst year was 2021 with a total return of -70.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 287.4 percentage points.